01 / DESIGN
What was studied?
This interim analysis covered 248 adults with overweight or obesity randomized at 20 hospitals in China. The primary assessment was weight change at 24 weeks.
02 / FINDINGS
What did the researchers report?
The mazdutide groups had greater average weight reduction than placebo. Diarrhea, nausea and upper respiratory tract infection were among the reported adverse events.
03 / LIMITS
How should it be interpreted?
The analysis concerns selected study groups and a short follow-up. Population characteristics and trial-specific eligibility matter when considering applicability elsewhere; the result is not evidence for every marketed material carrying the same name.
Loti Labs Peptide editorial reading note. Based on the linked source record. Methods and corrections.